Catheter Precision, Inc. (VTAK) Dividend History

Company News

• Catheter Precision, Inc. Receives CE Mark for LockeT

  Catheter Precision, a US-based medical device company, has received CE Mark approval for its LockeT vascular closure device, making it eligible for sale in the European Union and other countries. This approval opens up a multi-billion dollar market opportunity, with the European vascular closure devices market expected to grow to $4.3 billion by 2028.

  GlobeNewswire Inc.
• Catheter Precision, Inc. Announces $1.5 Million Private Placement Equity Financing and Potential Strategic Alliance

  Catheter Precision, Inc. announced a $1.5 million private placement equity financing and the acquisition of promissory notes from QHSLab, Inc. The company is pursuing a strategic partnership with QHSLab within the cardiovascular space.

  GlobeNewswire Inc.
• Catheter Precision Makes NYSE American Section 610(b) Public Announcement

  Catheter Precision, Inc., a U.S. medical device company, announced that it received a notice of the first patent allowance in the U.S. for its LockeT product line.

  GlobeNewswire Inc.
• Catheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy

  Catheter Precision, a medical device company, has engaged PCG Advisory to strengthen its investor engagement and communication efforts as it enters the commercial phase of its mission to deliver long-term value to shareholders and the healthcare sector.

  GlobeNewswire Inc.
• Catheter Precision announces reverse stock split - Investing.com

  Catheter Precision, Inc. (VTAK) announced a 1-for-10 reverse stock split to increase its per-share trading price and meet NYSE American listing requirements. The company also reduced its authorized common stock and expanded its equity incentive plan.

  Investing.com